A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G

Overview

Journal Target Oncol

Specialty Oncology

Date 2024 Mar 1

PMID 38427280

Authors

Toshihiko Matsumoto

Yoshiyuki Yamamoto

Masahito Kotaka

Toshiki Masuishi

Yasushi Tsuji

Hirokazu Shoji

Kenro Hirata

Takao Tsuduki

Akitaka Makiyama

Naoki Izawa

Naoki Takahashi

Masahiro Tsuda

Hisateru Yasui

Takashi Ohta

Yosuke Kito

Satoshi Otsu

Shuichi Hironaka

Kentaro Yamazaki

Narikazu Boku

Ichinosuke Hyodo

Kenichi Yoshimura

Kei Muro

Affiliations

Soon will be listed here.

Abstract

Background: Non-inferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) to irinotecan/fluoropyrimidine plus BEV in metastatic colorectal cancer was investigated in the phase III TRUSTY study, and we conducted a phase II study of FOLFIRI (5-FU+leucovorin+irinotecan) plus zib-aflibercept (AFL) after FTD/TPI plus BEV. However, the TRUSTY study failed during the recruitment of our patients.

Objective: We present the findings of a phase II study on the efficacy of FOLFIRI plus zib-aflibercept (AFL) after FTD/TPI plus BEV, including clinical results with plasma biomarker analyses.

Methods: This was a multicenter, single-arm, phase II study in patients with metastatic colorectal cancer refractory or intolerant to oxaliplatin, fluoropyrimidine, BEV, and FTD/TPI. The primary endpoint was progression-free survival. Fifteen plasma angiogenesis-associated biomarkers were analyzed using a Luminex multiplex assay U-kit.

Results: Between January 2020 and May 2022, 26 patients (median age, 68 years) from 15 sites were enrolled. The median progression-free survival was 4.9 months (85% confidence interval, 3.4 month-not estimated). The overall response and disease control rates were 8% and 62%, respectively. The median levels of vascular endothelial growth factor-A and placental growth factor, both targets of AFL, were below the measurable limit of 30 pg/mL and 16 pg/mL, respectively. Patients were divided into two groups at the median levels of baseline biomarkers. The progression-free survival did not differ between high and low expressers of placental growth factor (p = 0.7), while it tended to be shorter in those with high levels of osteopontin (p = 0.05), angiopoietin-2 (p = 0.07), and tissue inhibitor of matrix metalloproteinases-1 (p = 0.1).

Conclusions: This study did not meet the primary endpoint. Hence, FOLFIRI plus AFL should not be used after FTD/TPI plus BEV for metastatic colorectal cancer. Further studies are needed to determine factors not targeted by AFL that may affect the efficacy of the treatment.

Clinical Trial Registration: jRCTs041190100.

References

Bockelman C, Beilmann-Lehtonen I, Kaprio T, Koskensalo S, Tervahartiala T, Mustonen H . Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer. BMC Cancer. 2018; 18(1):679. PMC: 6013876. DOI: 10.1186/s12885-018-4589-x. View

Assidi M, Gomaa W, Jafri M, Hanbazazh M, Al-Ahwal M, Pushparaj P . Prognostic value of Osteopontin (SPP1) in colorectal carcinoma requires a personalized molecular approach. Tumour Biol. 2019; 41(9):1010428319863627. DOI: 10.1177/1010428319863627. View

Amilca-Seba K, Sabbah M, Larsen A, Denis J . Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers (Basel). 2021; 13(15). PMC: 8345080. DOI: 10.3390/cancers13153793. View

Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A . Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open. 2021; 6(2):100093. PMC: 7985393. DOI: 10.1016/j.esmoop.2021.100093. View

Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T . Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103(9):1407-14. PMC: 2990609. DOI: 10.1038/sj.bjc.6605925. View

Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K . Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016; 27(8):1539-46. DOI: 10.1093/annonc/mdw206. View

Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H . Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol. 2020; 26(1):111-117. DOI: 10.1007/s10147-020-01794-8. View

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T . Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499-506. DOI: 10.1200/JCO.2012.42.8201. View

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W . TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017; 18(9):1172-1181. DOI: 10.1016/S1470-2045(17)30425-4. View

10.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4):337-45. DOI: 10.1056/NEJMoa033025. View

11.

Kim H, Ahn T, Kim C, Bae S, Kim H, Lee C . Oncogenic function of angiopoietin-2 and its modulation of tumor progression in colorectal carcinoma. Oncol Lett. 2017; 14(1):553-560. PMC: 5494651. DOI: 10.3892/ol.2017.6203. View

12.

Zhao M, Liang F, Zhang B, Yan W, Zhang J . The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis. Sci Rep. 2015; 5:12713. PMC: 4522607. DOI: 10.1038/srep12713. View

13.

Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K . Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019; 110(11):3565-3572. PMC: 6825011. DOI: 10.1111/cas.14198. View

14.

Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M . Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. Target Oncol. 2024; 19(1):59-69. PMC: 10830797. DOI: 10.1007/s11523-023-01027-8. View

15.

Ishizaki T, Mazaki J, Enomoto M, Shigoka M, Kasahara K, Matsudo T . Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer. Anticancer Res. 2021; 41(4):2157-2163. DOI: 10.21873/anticanres.14988. View

16.

Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E . The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. Oncotarget. 2016; 7(35):57197-57212. PMC: 5302983. DOI: 10.18632/oncotarget.11084. View

17.

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen L . TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(3):412-420. DOI: 10.1016/S1470-2045(19)30827-7. View

18.

Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M . Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. Cancer Med. 2023; 12(18):18702-18716. PMC: 10557901. DOI: 10.1002/cam4.6486. View

19.

Van Cutsem E, Paccard C, Chiron M, Tabernero J . Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Analysis of the VELOUR Trial. Clin Cancer Res. 2019; 26(3):717-725. DOI: 10.1158/1078-0432.CCR-19-1985. View

20.

Sorensen N, Bystrom P, Christensen I, Berglund A, Nielsen H, Brunner N . TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res. 2007; 13(14):4117-22. DOI: 10.1158/1078-0432.CCR-07-0186. View